ARTICLE | Emerging Company Profile
Growth opportunities
How RondinX’s algorithms will shape microbiome-based drug development
February 23, 2017 6:56 PM UTC
Progress in harnessing the microbiome for drug development has been limited by the tools for identifying which bacteria drive disease and measuring their response to therapy. RondinX is developing next-generation computational algorithms to help with both.
Co-founder and CEO Guy Harmelin told BioCentury the “crown jewel” in RondinX’s platform is a peak-to-trough ratio (PTR) algorithm that can model the growth dynamics of a sample of microbes from a single metagenomic snapshot...